MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)

Clinical trials for MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST) explained in plain language.

Never miss a new study

Get alerted when new MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST) trials appear

Sign up with your email to follow new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug combo targets rare, aggressive nerve cancer

Disease control Recruiting now

This study is testing whether the drug combination ASTX727 can help control advanced malignant peripheral nerve sheath tumors (MPNST) that have a specific genetic change called PRC2 loss. The trial is for about 25 patients aged 16+ whose cancer has worsened after at least one sta…

Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)

Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)

Get alerted when new MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST) trials appear

New drug combo targets rare, aggressive nerve cancer